3B BlackBio Dx reports strong FY25 growth, acquires Coris Holding

3B BlackBio Dx Limited (formerly Kilpest India Limited) reported strong financial performance for the fiscal year 2024-25. Consolidated sales turnover reached ₹9,646.86 Lakh, a 30.14% increase from ₹7,412.47 Lakh in FY24. Net profit after tax also saw a substantial rise of 48.56% to ₹4,769.10 Lakh, up from ₹3,210.12 Lakh in the previous year. The company's molecular diagnostics business was a key driver, with sales growing to ₹8,428.50 Lakh in FY25 from ₹6,085.20 Lakh in FY24.

A significant strategic milestone was the acquisition of a 100% stake in Coris Holding SRL, Belgium, for an upfront cash consideration of £2.15 Million, with an earn-out of up to £0.615 Million. This acquisition aims to integrate Coris’s rapid diagnostic solutions with 3B BlackBio Dx's molecular diagnostics portfolio, broadening its product range and accelerating market access in Europe and globally. The company expects Coris to be EBITDA positive by FY26-27.

The board of directors has proposed a dividend of ₹4/- per equity share for FY25, subject to shareholder approval. International business, excluding COVID-related sales, grew over 97%, driven by higher order volumes from its UK subsidiary and new contracts. The company projects 20-25% growth in international business for FY26.